Serrated Polyp Yield at Colonoscopy in Patients with Positive FIT, Positive mt-sDNA, and Colonoscopy Only: Data from the New Hampshire Colonoscopy Registry

Anderson, Joseph C.; Hisey, William; Robinson, Christina M.; Limburg, Paul J.; Kneedler, Bonny; Butterly, Lynn F.

doi:10.1158/1055-9965.epi-22-0527

Cited by 8 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…140 The multitarget stool DNA test is an advance in home-based alternatives because, with real-world adherence, it results in more life-years gained than fecal immunochemical testing (FIT) or high-sensitivity guaiac-based fecal occult blood testing. 141 Multitarget stool DNA testing is also more sensitive than fecal immunochemical testing or colonoscopy alone for serrated polyps, 142 which are precursors for 15%-30% of all CRCs, including many interval cancers. 143,144 However, although the 3-year screening schedule for multitarget stool DNA testing may be less burdensome than annual testing, the cost remains substantially higher compared to other stool tests.…”

Section: Colorectal Cancer Screeningmentioning

confidence: 99%

Colorectal cancer statistics, 2023

Siegel

Wagle

Cercek

et al. 2023

CA A Cancer J Clinicians

1,232

459

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second most common cause of cancer death in the United States. Every 3 years, the American Cancer Society provides an update of CRC statistics based on incidence from population‐based cancer registries and mortality from the National Center for Health Statistics. In 2023, approximately 153,020 individuals will be diagnosed with CRC and 52,550 will die from the disease, including 19,550 cases and 3750 deaths in individuals younger than 50 years. The decline in CRC incidence slowed from 3%–4% annually during the 2000s to 1% annually during 2011–2019, driven partly by an increase in individuals younger than 55 years of 1%–2% annually since the mid‐1990s. Consequently, the proportion of cases among those younger than 55 years increased from 11% in 1995 to 20% in 2019. Incidence since circa 2010 increased in those younger than 65 years for regional‐stage disease by about 2%–3% annually and for distant‐stage disease by 0.5%–3% annually, reversing the overall shift to earlier stage diagnosis that occurred during 1995 through 2005. For example, 60% of all new cases were advanced in 2019 versus 52% in the mid‐2000s and 57% in 1995, before widespread screening. There is also a shift to left‐sided tumors, with the proportion of rectal cancer increasing from 27% in 1995 to 31% in 2019. CRC mortality declined by 2% annually from 2011–2020 overall but increased by 0.5%–3% annually in individuals younger than 50 years and in Native Americans younger than 65 years. In summary, despite continued overall declines, CRC is rapidly shifting to diagnosis at a younger age, at a more advanced stage, and in the left colon/rectum. Progress against CRC could be accelerated by uncovering the etiology of rising incidence in generations born since 1950 and increasing access to high‐quality screening and treatment among all populations, especially Native Americans.

show abstract

Section: Colorectal Cancer Screeningmentioning

confidence: 99%

Colorectal cancer statistics, 2023

Siegel

Wagle

Cercek

et al. 2023

CA A Cancer J Clinicians

1,232

459

View full text Add to dashboard Cite

show abstract

“…Previous efforts to improve the detection of SSLs in the colon have included methods to examine methylation patterns in DNA (12)(13)(14)(15), chromoendoscopy with narrow band imaging (16), color enhancement (17,18), and novel artificial intelligence approaches (19). Despite these efforts, no single modality has gained acceptance due to cost and modest sensitivity (14).…”

Section: Introductionmentioning

confidence: 99%

Mucin 5AC is a sensitive surface marker for sessile serrated lesions: results from a systematic review and meta-analysis

Liu,

Sachar,

Popov

et al. 2024

Preprint

View full text Add to dashboard Cite

Sessile serrated lesions (SSLs) are a class of colon polyps which are challenging to detect through current screening methods but are highly associated with colon cancer. We reasoned that a biomarker sensitive for SSLs would be clinically useful to improve detection. Recent endoscopic and histopathologic studies suggest that SSLs are associated with alterations in intestinal mucin expression but the frequency with which this occurs is not known. We performed a meta-analysis of available pathologic studies comparing mucin expression on SSLs to normal colonic mucosa, tubular adenomas (TAs), villous adenomas (VAs), traditional serrated adenomas (TSAs), and hyperplastic polyps (HPs). We searched Medline, Pubmed, and Embase and found 440 publications in this topic, and 18 total studies met inclusion. We found that MUC5AC expression was more common in SSLs compared to normal colonic mucosa (OR=82.9, p<0.01), TAs (OR=11, p<0.01), and TSAs (OR=3.6, p=0.04). We found no difference in MUC5AC expression between SSLs versus HPs (OR=2.1, p=0.09) and no difference in MUC5AC expression between left colon and right colon HPs, with an OR=1.8, p=0.23. We found that MUC5AC expression was found commonly on VAs, SSLs, and TSAs while the frequency on colon cancers declined. MUC5AC is also upregulated in inflammatory bowel disease and in response to intestinal infections. MUC5AC expression highlights the potential of mucins as sensitive biomarkers, though not specific to SSLs. Further research into the clinical utilization of MUC5AC could enhance SSL detection.

show abstract